Key result
Neuroleptic malignant syndrome is a potentially lethal, underdiagnosed idiosyncratic reaction to neuroleptic agents that requires early recognition and specific treatments to decrease morbidity and mortality.
This review summarizes the major features, supportive therapy, and investigational treatments for neuroleptic malignant syndrome, along with guidelines for restarting neuroleptic therapy.
PreviewThe neuroleptic malignant syndrome (NMS) is an idiosyncratic reaction to neuroleptic agents that consists of fever, mental status changes, muscle rigidity, autonomic dysfunction, respiratory distress, and rhabdomyolysis. This potentially lethal disease is not widely recognized and is probably underdiagnosed, but early recognition and therapy may decrease morbidity and mortality. The authors summarize the major features of NMS and review supportive therapy and specific investigational treatment with anticholinergics, muscle relaxants, and dopamine agonists. They also offer guidelines for restarting therapy with neuroleptics in patients recovering from NMS.
No takes yet. Share an insight, caveat, or question.
Lavie et al. (1986) conducted a review in Neuroleptic malignant syndrome. Supportive therapy and investigational treatments (anticholinergics, muscle relaxants, dopamine agonists) was evaluated. Neuroleptic malignant syndrome is a potentially lethal, underdiagnosed idiosyncratic reaction to neuroleptic agents that requires early recognition and specific treatments to decrease morbidity and mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: